Health ❯Healthcare ❯Clinical Trials

Drug Development

Combination Therapy Alzheimer's Treatments Targeted Therapy Phase III Trials Phase 2 Trials Eli Lilly Azelaprag Lenacapavir Oral Medications Targeted Therapies

Extended LRRK2 Inhibition Reverses Parkinson’s Neuronal Damage in Mice

This approach marks the first reversal of early neuronal damage in genetic Parkinson’s models, pointing toward disease-modifying therapies.

Cidara’s CD388 Antiviral Achieves Up to 76% Flu Protection in Phase 2b Trial

Dual Enzyme Inhibitors Convert Neuroblastoma Tumors into Healthy Neurons in Mice

Zigakibart sustains proteinuria remission and stabilizes kidney function over 100-week IgA nephropathy trial

New Triple-Drug Regimen Boosts Survival in PIK3CA-Mutant HR+ HER2- Breast Cancer

Triplet Therapy Doubles Survival in BRAF V600E Metastatic Colorectal Cancer

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab

Cancer drug pair extends mouse lifespan by 30% as researchers plan human trials

UCSF Research Advances Prenatal Therapy for Spinal Muscular Atrophy

New Data Confirms Low Risk of Severe Side Effects for Alzheimer’s Drug Lecanemab

Weight Management Revolution: GLP-1 Drugs Dominate as Pills Emerge

Living Human Brain Tissue Provides Breakthrough Insights Into Alzheimer’s Disease

First Human Trial of Type 1 Diabetes Immunotherapy Underway in Australia

PLT012 Antibody Advances Toward Clinical Trials as Promising Cancer Immunotherapy

LUT014 Gel Shows Promise in Reducing Severe Rash from Colorectal Cancer Therapy

Eli Lilly's Oral GLP-1 Pill Demonstrates Success in Phase 3 Trials

Verve-102 Gene-Editing Therapy Shows Promising LDL Cholesterol Reduction in Early Trial

Breakthrough Blood Test for Alzheimer’s Diagnoses Disease and Tracks Progression

Study Suggests Long-Term Anti-Amyloid Therapy May Delay Early-Onset Alzheimer’s

Novo Nordisk's CagriSema Falls Short in Latest Weight-Loss Trial for Diabetes Patients